Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.

Bethany C Prudner Richa RathoreAnthony M RobinsonAbigail GodecSamuel F ChangWilliam G HawkinsAngela C HirbeBrian Andrew Van Tine

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

The priming of tumors with ADI-PEG20 and DTX results in the stabilization of c-MYC potentiating the effect of GEM treatment via an increase in hENT1 expression. This finding is applicable to ASS1-deficient cancers that are currently treated with GEM.

Keyphrases

poor prognosis
binding protein
drug delivery
radiation therapy
combination therapy